Latest Headlines
-
Samsung Invests In BrickBio To Develop Advanced Molecules And Therapies Using Protein Engineering Technology For Antibody-Drug Conjugates (ADC)
3/18/2024
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
-
Selvita Launches Biologic Drug Discovery And Development Services
3/18/2024
Selvita S.A. announced today a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio.
-
U.S. Food And Drug Administration (FDA) Has Accepted The New Drug Application (NDA) For Ensartinib
3/13/2024
Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).
-
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted To P-BCMA-ALLO1 For The Treatment Of Multiple Myeloma
3/13/2024
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.
-
Allumiqs And Prolytix Form Strategic Partnership To Accelerate Drug Discovery And Development
3/13/2024
Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines. Together the partners empower customers with bioanalytical solutions to advance drug candidates from the early R&D phases through to lot release.
-
UCT’s H3D Spearheads Africa’s Drug Discovery Accelerator Programme
3/13/2024
The University of Cape Town’s (UCT) Drug Discovery and Development Centre (H3D) will play a pivotal role in supporting the Grand Challenges African Drug Discovery Accelerator (GC ADDA) network as they advance nascent drug discovery research through the support of LifeArc and the Bill & Melinda Gates Foundation.
-
UCF Researcher Pioneers Chiral Molecule Sensing Method To Enhance Drug Development
3/13/2024
Promising UCF technology is illuminating new ways to examine molecules with precision, an advancement that can help enhance drug development and new therapies.
-
Automated High-Throughput Sorting Of Living Cells Using Laser Light And AI
3/12/2024
Tests on living cell cultures are becoming increasingly important for personalized medicine, drug development and clinical research.
-
AION Labs Launches CombinAble.AI To Reduce Time And Cost Of Targeted Antibody Design, Advancing Optimization Of Drug Development
3/12/2024
AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the launch of CombinAble.AI.
-
GV20 Therapeutics Joins NVIDIA Inception To Develop AI Models For Drug And Target Discovery
3/12/2024
GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.